SEC Form 4 · accession 0001209191-18-003986
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Altshuler
Officer — EVP, Global Research and CSO
Period of report
Jan 16, 2018
Accepted (ET)
Jan 17, 2018 · 4:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jan 16, 2018 | S | 23,813 | $155.77 | D | 82,198 | D | |
| Common StockF3,F4 | Jan 16, 2018 | S | 11,767 | $156.63 | D | 70,431 | D | |
| Common StockF3,F5 | Jan 16, 2018 | S | 6,130 | $157.71 | D | 64,301 | D | |
| Common StockF3,F6 | Jan 16, 2018 | S | 10,585 | $158.82 | D | 53,716 | D | |
| Common StockF3,F7 | Jan 16, 2018 | S | 3,955 | $159.41 | D | 49,761 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $155.77 (range $155.19 to $156.17).
- F3Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $156.63 (range $156.19 to $157.18).
- F5Open market sales reported on this line occurred at a weighted average price of $157.71 (range $157.20 to $158.19).
- F6Open market sales reported on this line occurred at a weighted average price of $158.82 (range $158.21 to $159.20).
- F7Open market sales reported on this line occurred at a weighted average price of $159.41 (range $159.21 to $159.65).